FDA Bans Juul E-cigarettes Sales in US, Experts React

Jul.26.2022
FDA Bans Juul E-cigarettes Sales in US, Experts React
US FDA bans Juul e-cigarettes due to concerns about their marketing towards youth. No evidence they help tobacco consumption.

A report by Medscape reveals that the United States Food and Drug Administration (FDA) has banned the sale of Juul brand e-cigarettes in the country. Dr. Pierre Bizel, a member of Belgium's national anti-tobacco alliance, believes that the primary intention of these products is to attract more smokers and there is no scientific evidence to suggest that e-cigarettes help eliminate tobacco consumption.


The FDA has announced that Juul Labs and their USB-shaped e-cigarettes and flavored nicotine pods have failed to demonstrate that their marketing is "appropriate for the protection of public health." The San Francisco-based startup has been accused of playing a significant role in the surge of youth e-cigarette use, particularly through advertising and marketing aimed at high school students, in an effort to justify its decision.


In 2021, Juul Labs paid $51,000 to fully fund the May-June issue of the American Journal of Health Behavior, which published 11 studies sponsored by Juul that aimed to demonstrate how their products help smokers quit smoking. While all articles underwent peer review (with the twelfth article being rejected), there are questions about the legitimacy of the process from the academic community. The version of the journal has been described by the American Prospect as "taking academic corruption to a new level.


A study that appeared in Tobacco Control in 2021 indicated that less than half of the scientific conclusions in clinical trials sponsored by Juul Labs were accurate. In response to regulatory pressure, the company suspended the sale of flavored pods popular among young people in 2019 and agreed to review its marketing strategies.


MediQuality interviewed Bizel, who is also the Director of Lifestyle Habits Research at the Belgian Health Observatory in Halle.


Is Juul electronic cigarette widely considered a trojan horse that attracts young smokers, according to MediQuality today?


Bizel stated that Juul products were withdrawn from the Belgian market in 2019, but it is clear that they appeal to young people. Resembling a USB stick, the product can be charged on a laptop and comes with separate pods offering different flavors. The product is clearly designed to attract teenagers and young adults, and is not targeted towards responsible adult smokers seeking a way to quit smoking. Such e-cigarettes can only create addiction and then increase the number of smokers. Like other products currently available, such as Puff Bar, the aim remains the same: these fluorescent or candy pink disposable e-cigarettes produce little smoke, are highly discreet, have a very high nicotine content, and attract consumers. After all, these are products manufactured by nicotine sellers.


The Belgian Alliance for Smoke-Free Society believes that e-cigarettes need to attract new customers. However, according to a recent statement by the Belgian Superior Health Council, these products are "not harmless". As such, they pose a risk to young people who need to be protected from their harmful effects.


The device can certainly play a role in smoking cessation, but only in specific circumstances, much like any medication used to aid in treatment. Otherwise, its effectiveness will be very low. Without consultation, doctors, or behavioral support, relapse is almost certain. The device can only be used in a therapeutic environment, much like many other tools. Unfortunately, no e-cigarette manufacturer - Juul or any other company - has applied for marketing authorization for such products to eliminate tobacco consumption. As a result, drug agencies from different countries are unable to assess their positive effects on eliminating tobacco consumption and approve them.


Regardless of what type of cigarette-like aerosol may be presented, no manufacturer can claim that these devices are aids to quitting smoking. Manufacturers are promoting these devices as another way to smoke or as a replacement, but they are not official tools for smoking cessation. While scholars and researchers are attempting to determine the potential benefits of such products, it has not been officially declared as an auxiliary tool to counter tobacco consumption. There is ambiguity involved.


Is the only acceptable electronic cigarette device one that is proven effective and sold in pharmacies, according to MediQuality?


Bizel stated that the manufacturer's strategy does not focus on establishing a presence in the medical field nor gaining the support of tobacco addiction experts or smoking cessation hotlines. Instead, their goal is to create a consumer product that generates as many nicotine-dependent smokers as possible. They have no interest in developing a presence in the treatment industry. Therefore, it is essential to note that the only guarantee of efficacy is through supervision and gradual dose reduction.


This is a market seeking long-term dependence, as there are currently no time restrictions for users of this product. It is important to note, as shown by the national health survey conducted by Belgium's public health research institute, Sciensano, and a survey by the Belgian Cancer Foundation, that 70% of e-cigarette users also smoke traditional cigarettes, making them dual users. This raises questions about the effectiveness of e-cigarettes as a smoking cessation tool, as if they were effective, users would quit smoking altogether. In fact, e-cigarettes increase the overall intake of nicotine, which in turn increases the number of products in circulation and manufacturers' profits. When looking at the big picture, both in Belgium and globally, e-cigarettes have not made any changes to cigarette sales. The same amount of traditional tobacco is still being sold. This new product allows manufacturers to profit from both sides.


Will Juul electronic cigarettes disappear forever, according to MediQuality?


Bizel expressed surprise at the possibility of Juul e-cigarettes returning to the market, but notes that other e-cigarettes are still widely available. A notable recent development in the US is the reduction of nicotine levels in cigarettes by approximately 90%. While this is a significant step towards normalizing cigarette use, it must be properly validated, particularly considering the variety of nicotine types such as salt nicotine and freebase nicotine. This initiative is part of a broader ambitious public health plan to reduce cancer deaths, with President Joe Biden committing to a 50% reduction in cancer deaths within 25 years. However, the five major tobacco companies will need to react, meaning change will not happen overnight.


I am sorry, but as an AI language model, I am already programmed to generate news articles in standard journalistic English. Can you please provide me with a text that needs to be translated?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
The Texas Comptroller of Public Accounts ruled in September 2026 that a combustible product made with non-tobacco plant material and 6-methylnicotine (6-MN), a synthetic nicotine analog, qualifies as a taxable tobacco product. The applicant said the product contained neither tobacco leaf nor measurable conventional nicotine. The determination applies reasoning from a May Texas Supreme Court decision involving VELO nicotine pouches, finding that the plant material and 6-MN together perform the functions of tobacco in a conventional smoking product. The ruling carries applicable tax, licensing and reporting obligations but is limited to the facts submitted by the taxpayer. It does not establish a blanket tax classification for all 6-MN products or extend the same conclusion to e-cigarettes.
Regulations
Nov.06
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Special Report|From CrossBar 20K to 6-Methyl Nicotine KUMI: Two Routes Into U.S. State Vape Directories?
Several U.S. states have incorporated the September 9, 2020 PMTA filing deadline into eligibility rules for certain vaping products. CrossBar 20K drew attention after appearing on Pennsylvania's 163-entry directory. A broader 2Firsts investigation found that related registration businesses also listed KUMI and CROSSBAR SIX products, with 171 KUMI-related entries across Louisiana, Nebraska and Wisconsin. Corporate records link Scott Silverman to Blue Nine LLC and VR Products I LLC. PMTA compliance expert Mr. K said historical applications and nicotine-analogue products may offer two different approaches to state-directory access.
Regulations
Oct.26
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Q3 Sales Rise 11%, but New Products Generate Just $2.1 Million in Nine Months as U.S. Vape Push Awaits FDA Review
AIR Global PLC (NASDAQ: AIIR), a producer of flavored shisha tobacco and next-generation nicotine products, reported an 11.1% increase in third-quarter 2026 revenue to $99.8 million and a 7.7% rise in adjusted EBITDA to $30.9 million. Revenue for the first nine months increased 6.0% to $306.7 million, but the company posted a $74.2 million net loss, affected by listing-related expenses and other costs. Its New Growth Categories (NGC) business generated $2.1 million in nine-month revenue and an adjusted EBITDA loss of $10.8 million. AIR maintained its 2026 revenue growth guidance of 4%–6%, while lowering its capital expenditure outlook and raising its year-end leverage forecast from approximately 2.1 times to 2.5 times. The company has submitted a U.S. PMTA for its Crown Switch pod vape, with future contributions from new products dependent on regulatory progress and commercialization.
Capital Markets
Nov.13
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
EU Vape, Heated Tobacco and Nicotine Pouch Tax Reform Reaches Ministerial Talks: Sweden Opposes Proposed 2032 Minimum of 50% of Retail Price or €50/kg for Nicotine Pouches
EU Vape, Heated Tobacco and Nicotine Pouch Tax Reform Reaches Ministerial Talks: Sweden Opposes Proposed 2032 Minimum of 50% of Retail Price or €50/kg for Nicotine Pouches
EU finance ministers are scheduled to discuss tobacco excise reform on November 9, 2026, seeking agreement on higher minimum duties for conventional tobacco and a common EU minimum tax framework covering e-cigarettes, heated tobacco and nicotine pouches. A November 5 Council document identifies nicotine pouch taxation as the main outstanding issue. The Irish Council presidency proposes phased increases, reaching 50% of retail selling price or €50 per kilogram in 2032. Sweden has formally said it cannot support the current compromise, objecting to both the proposed nicotine pouch tax burden and the adjustment of minimum rates based on national purchasing power. The package also addresses cross-border personal-use reference quantities, raw tobacco controls and the continued exclusion of traditional tobacco snus.
Regulations
Nov.10